Liver cancer is one of the five most common malignancies in the world, with an incidence of 5 in male malignancies being the second leading cause of death and 7 in women being the sixth leading cause of death.
Hepatocellular carcinoma (HCC) is the main histological form of liver cancer, the main treatment methods include surgical resection, liver transplantation, local ablation, TACE, and others. In the last 50 years, although drug therapy for HCC has undergone clinical trials, few satisfactory results have been obtained for hepatocellular disease prevention.
PROTAC, a small heterobifunctional molecule consisting of a linker and two warheads, one of which binds to a target protein and the other builds an E3 ligase, activates the body's protein breakdown system (USV) to selectively break down pathogenic proteins. As a new and promising field of drug discovery, it has the following advantages.
It breaks down pathogenic proteins instead of inhibiting them
– Low dose
– Toxicity reduction
– Target Whole Protein
– Longer pharmacodynamic effect
The abnormal UPS pathway causes the accumulation of abnormal proteins in vivo, which will lead to various diseases. This mechanism allows the novel and innovative PROTAC approach to play an important role in restoring normal physiological tissues by blocking, dispersing and destroying pathogenic proteins.
Appropriate drug discovery projects deserve attention and support that hope to offer therapeutic interventions beyond the bounds of existing approaches to diseases of human systems and organs: nervous system, immune system, heart, liver , kidney, and others.